Clinical trials in Linz – page 7

419 clinical trials in Linz, Austria across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Linz at a glance

419

clinical trials

Research sites4

Quick filters

419 trials in Linz

Open in trial search

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Prostate cancer

Recruiting

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Amgen Inc.

Contact Research Centre

Astrocytoma malignant

Recruiting

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Vorasidenib
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Adenocarcinoma gastric+2

Recruiting

A study comparing injection under the skin versus infusion into the vein of tislelizumab with chemotherapy for patients with advanced gastric or gastroesophageal junction cancer

Registered drugNo placebo

A study comparing injection under the skin versus infusion into the vein of tislelizumab with chemotherapy for patients with advanced gastric or gastroesophageal junction cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Tislelizumab
Sponsor:BeOne Medicines AG

Contact Research Centre

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Glioblastoma

Recruiting

Study of iodofalan (131I) and lomustine combination therapy compared to lomustine alone in patients with first recurrent glioblastoma

Registered drugNo placebo

Study of iodofalan (131I) and lomustine combination therapy compared to lomustine alone in patients with first recurrent glioblastoma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Lomustine
Sponsor:Telix Pharmaceuticals (Innovations) Pty Limited

Contact Research Centre

Dry age-related macular degeneration

Recruiting

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Xelafaslatide
Sponsor:ONL Therapeutics Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Dupilumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

IgA nephropathy

Recruiting

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger's Disease) to Reduce Protein in Urine

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Mezagitamab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Secondary immunodeficiency

Recruiting

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Teclistamab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Linz

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on various forms of cancer, including prostate cancer, colorectal cancer, and lung cancer. Studies are evaluating novel therapeutic approaches and combination treatments.

Metastatic cancer treatments
Immunotherapy combinations
Novel drug therapies

Particular emphasis on personalized treatment approaches and targeted therapies for specific cancer types.

02 Autoimmune Conditions

Research targeting inflammatory and autoimmune disorders, including Crohn's Disease, plaque psoriasis, and uveitis. Studies evaluate new biological treatments and combination therapies.

Inflammatory disease management
Novel biological agents
Treatment resistance solutions

Focus on improving disease control and patient outcomes through innovative therapeutic approaches.

03 Cardiovascular and Metabolic Studies

Trials investigating treatments for cardiovascular disease and obesity, with emphasis on preventive measures and innovative therapeutic solutions.

Cardiovascular risk reduction
Metabolic disorder management
Safety assessments

Research aimed at developing safer and more effective treatments for metabolic and cardiovascular conditions.

Back to Austria All countries